Weekly NIH Funding Opportunities and Notices for January 29, 2021

Policy Notices

- Notice of Legislative Mandates in Effect for FY 2021 (NOT-OD-21-056)
  National Institutes of Health

- Guidance on Salary Limitation for Grants and Cooperative Agreements FY 2021 (NOT-OD-21-057)
  National Institutes of Health

- Notice of Fiscal Policies in Effect for FY 2021 (NOT-OD-21-058)
  National Institutes of Health

General Notices

- Notice of Pre-Application Information Webinar and Frequently Asked Questions (FAQs) for RFA-DA-21-020, RFA-DA-21-021, RFA-DA-21-022, and RFA-DA-21-023 (NOT-DA-21-027)
  National Institute on Drug Abuse

- Notice of Clarification of Award Budget for RFA-HD-21-023, NICHD Program Project Grants for HIV Research (P01 Clinical Trial Optional) (NOT-HD-21-008)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development

- Ruth L. Kirschstein National Research Service Award (NRSA) Stipends, Tuition/Fees and Other Budgetary Levels Effective for Fiscal Year 2021 (NOT-OD-21-049)
  National Institutes of Health
  Agency for Healthcare Research and Quality
  Health Resources and Services Administration

- Notice of Intent to Publish a Funding Opportunity Announcement for Advancing Gender Inclusive Excellence (AGIE) Coordinating Center (U54) (NOT-OD-21-051)
  Office of Research on Women's Health
  National Institute of Diabetes and Digestive and Kidney Diseases

- Notice of Pre-Application Webinar for the Common Funds Nutrition for Precision Health Program RFAs (NOT-RM-21-013)
  Office of Strategic Coordination (Common Fund)
Notice of Changes to Funding Opportunities

- Notice of NIAID's Participation in PAR-19-039: Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01 Clinical Trial Not Allowed) (NOT-AI-21-026)
  National Institute of Allergy and Infectious Diseases

- Notice of NIAID's Participation in PAR-19-040: Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional) (NOT-AI-21-027)
  National Institute of Allergy and Infectious Diseases

- Notice of NIAID's Participation in PAR-20-253: Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects (R21 Clinical Trial Not Allowed) (NOT-AI-21-028)
  National Institute of Allergy and Infectious Diseases

- Notice of NIAID's Participation in PAR-20-316: NIH Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 - Clinical Trial Optional) (NOT-AI-21-029)
  National Institute of Allergy and Infectious Diseases

- Notice of Change to RFA-DA-21-016, "Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R43/R44 - Clinical Trials Optional)" (NOT-DA-21-057)
  National Institute on Drug Abuse

- Notice of NIDA's Participation in NOT- MD-21-008 "Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities" (NOT-DA-22-015)
  National Institute on Drug Abuse

- Notice of change to Eligible Organizations under RFA-FD-21-023 "National Food and Nutrient Analysis Program (U01) Clinical Trial Not Applicable" (NOT-FD-21-006)
  Food and Drug Administration

- Notice of Change to Key Dates for Cellular Senescence Network (SenNet) RFA-RM-21-008 "Cellular Senescence Network: Tissue Mapping Centers (U54 Clinical Trial Not Allowed)" (NOT-RM-21-011)
  Office of Strategic Coordination (Common Fund)
• Notice of Termination of RFA-TR-20-030 "Multi-disciplinary Machine-assisted, Genomic Analysis and Clinical Approaches to Shortening the Rare Diseases Diagnostic Odyssey (UG3/UH3 Clinical Trial Not Allowed)
  (NOT-TR-21-018)
  National Center for Advancing Translational Sciences

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trials Not Allowed)
  (NOT-AA-21-001)
  National Institute on Alcohol Abuse and Alcoholism

• Notice of Intent to Publish a Funding Opportunity Announcement for SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R03 Clinical Trials Not Allowed)
  (NOT-AA-21-002)
  National Institute on Alcohol Abuse and Alcoholism

• Notice of Intent to Publish a Funding Opportunity Announcement for SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R21 Clinical Trials Not Allowed)
  (NOT-AA-21-003)
  National Institute on Alcohol Abuse and Alcoholism

• Notice of Intent to Publish Funding Opportunity Announcements for Research on Firearm Injury and Mortality Prevention
  (NOT-OD-21-059)
  Office of Behavioral and Social Sciences Research

Notices of Special Interest

• Notice of Special Interest (NOSI): Aging-Relevant Behavioral and Social Research on Coronavirus Disease 2019 (COVID-19)
  (NOT-AG-21-015)
  National Institute on Aging

• Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers
  (NOT-CA-21-028)
  National Cancer Institute

• Notice of Special Interest (NOSI): Understanding the effects of cancer and cancer treatment on aging trajectories and aging outcomes
  (NOT-CA-21-031)
  National Cancer Institute
  National Institute on Aging

• Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection
  (NOT-DA-21-011)
  National Institute on Drug Abuse

• Notice of Special Interest (NOSI): High-Priority Interest to Enhance Data Science Research Training in Addiction Research

Funding Opportunities

- **NIA MSTEM: Advancing Diversity in Aging Research through Undergraduate Education (R25 Independent Clinical Trial Not Allowed)** (PAR-20-317) National Institute on Aging Application Receipt Date(s): May 25, 2021; May 25, 2022; May 25, 2023

- **NIA Academic Leadership Career Award (K07 Independent Clinical Trial Not Allowed)** (PAR-21-106) National Institute on Aging Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is June 12, 2021.

- **NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed)** (PAR-21-114) National Institute of Neurological Disorders and Stroke Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is April 5, 2021.

- **The Cellular Scale Connectome in Aging and Alzheimer's Disease (U01 Clinical Trial Not Allowed)** (RFA-AG-22-008) National Institute on Aging Application Receipt Date(s): June 15, 2021

- **NIH Blueprint for Neuroscience Research: Tools and Technologies to Explore Nervous System Biomolecular Condensates (R21 Clinical Trial Not Allowed)** (RFA-DA-22-008) National Institute on Drug Abuse National Center for Complementary and Integrative Health National Eye Institute National Institute on Aging National Institute on Alcohol Abuse and Alcoholism National Institute of Biomedical Imaging and Bioengineering Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institute of Dental and Craniofacial Research National Institute of Environmental Health Sciences National Institute of Mental Health National Institute of Neurological Disorders and Stroke Office of Behavioral and Social Sciences Research Application Receipt Date(s): September 15, 2021

NIH Funding Opportunities now available in RSS (Really Simple News Syndication) format - see https://grants.nih.gov/grants/guide/rss_info.htm for details.

To UnSubscribe from the NIH Guide Weekly TOC LISTSERV, follow the in